Related Experiment Videos
Randomized controlled trial of standard versus double dose cotrimoxazole for childhood pneumonia in Pakistan
Zeba A Rasmussen1, Abdul Bari, Shamim Qazi
1Department of Community Health Sciences, Aga Khan University, House 32B Street 25, Secotr F-8-2 Islamabad, Pakistan. zeba@comstats.net.pk
Objective:
Increasing concern over bacterial resistance to cotrimoxazole, which is recommended by WHO as a first-line drug for treating non-severe pneumonia, led to the suggestion that this might not be optimal therapy. However, changing to alternative antimicrobial agents, such as amoxicillin, is costly. We compared the clinical efficacy of twice-daily cotrimoxazole in standard versus double dosage for treating non-severe pneumonia in children.
Methods:
A randomized controlled multicentre trial was implemented in seven hospital outpatient departments and two community health programmes. A total of 1143 children aged 2-59 months with non-severe pneumonia were randomly allocated to receive 4 mg trimethoprim plus 20 mg sulfamethoxazole/kg of body weight or 8 mg trimethoprim plus 40 mg sulfamethoxazole/kg of body weight orally twice-daily for 5 days Treatment failure occurred when a child required a change of therapy, died or was lost to follow-up. Children required a change of therapy if their condition worsened (they developed chest indrawing or danger signs) or if at 48 hours after enrollment, their clinical condition was the same (defined as having a respiratory rate that was 5 breaths/minute higher or lower than at the time of enrollment).
Findings:
The results of 1134 children were analysed: 578 were assigned to the standard dose of cotrimoxazole and 556 to the double dose. Treatment failed in 112 children (19.4%) in the standard group and 118 (21.2%) in the double-dose group (relative risk 1.10; 95% confidence interval = 0.87-1.37). Using multivariate analysis we found that treatment was more likely to fail in children who were not given the medicine correctly (P = 0.001), in those younger than 12 months (P = 0.004), those who had used antibiotics previously (P = 0.002), those whose respiratory rate was > or =20 breaths/minute above the age-specific cut-off point (P = 0.006), and those from urban areas (P = 0.042).
Conclusion:
Both standard and double strength cotrimoxazole were equally effective in treating non-severe pneumonia. Close follow-up of patients is essential to prevent worsening of disease. Definitions of clinical failure need to be more specific. Surveillance in both rural and urban areas is essential in the development of treatment policies that are based on clinical outcomes.
Insights
Standard and double doses of cotrimoxazole showed equal efficacy for treating childhood pneumonia. Close patient follow-up is crucial for preventing disease progression and informing treatment policies.
Area of Science:
- Pediatric Infectious Diseases
- Antimicrobial Stewardship
- Clinical Pharmacology
Background:
- Bacterial resistance to cotrimoxazole raises concerns for treating childhood pneumonia.
- WHO recommends cotrimoxazole as a first-line treatment for non-severe pneumonia.
- Alternative antibiotics like amoxicillin present cost challenges.
Purpose of the Study:
- To compare the clinical efficacy of standard versus double dosage of cotrimoxazole for non-severe pneumonia in children.
- To evaluate treatment outcomes based on different cotrimoxazole dosing regimens.
Main Methods:
- A randomized controlled multicentre trial involving 1143 children aged 2-59 months with non-severe pneumonia.
- Children received either standard or double oral doses of cotrimoxazole (trimethoprim/sulfamethoxazole) twice daily for 5 days.
- Treatment failure was defined by need for therapy change, death, or loss to follow-up.
Main Results:
- Treatment failure rates were similar between standard (19.4%) and double-dose (21.2%) cotrimoxazole groups (RR 1.10; 95% CI 0.87-1.37).
- Factors associated with treatment failure included incorrect medication administration, younger age (<12 months), prior antibiotic use, elevated respiratory rate, and urban residence.
- Multivariate analysis identified specific predictors of treatment failure.
Conclusions:
- Standard and double doses of cotrimoxazole demonstrate comparable efficacy in treating non-severe childhood pneumonia.
- Emphasizes the critical need for close patient monitoring to prevent disease exacerbation.
- Highlights the necessity for refined clinical failure definitions and comprehensive surveillance for evidence-based treatment policy development.
